* Resistance was linked to chromosome mutations, and treatment varied, with 8 patients on monotherapy and 19 on combination therapy; the overall mortality rate was 37%.
* In vitro tests showed a 74% synergy rate for combination therapies using colistin, amikacin, and tigecycline, but no significant survival difference was found based on drug combinations; major risk factors for mortality included dialysis and shock.